Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

The Trade Desk Faces Analyst Downgrade Amid CTV Growth Concerns

Robert Sasse by Robert Sasse
September 11, 2025
in Analysis, Nasdaq, Tech & Software
0
The Trade Desk Stock
0
SHARES
164
VIEWS
Share on FacebookShare on Twitter

A significant analyst downgrade has sent shockwaves through the market for The Trade Desk shares. Morgan Stanley has slashed its price target for the advertising technology company from $80 to $50, representing a 37.5% reduction, while simultaneously downgrading the stock from “Overweight” to “Neutral.” The investment bank cited mounting concerns about the company’s connected television business segment as the primary reason for this revised assessment.

Market Volatility and Performance Pressure

The timing of this downgrade adds pressure to an already volatile stock. The Trade Desk shares have experienced substantial price swings throughout the year, recording 26 separate moves exceeding 5% in either direction. Currently trading approximately 60% below its yearly peak, the stock has lost two-thirds of its value since reaching its 52-week high of $139.51 in December 2024.

Despite reporting solid second-quarter 2025 results with revenue of $694 million – representing 19% year-over-year growth – the company faces increasing skepticism about its growth trajectory. Weaker-than-expected guidance for the third quarter has further amplified investor concerns about The Trade Desk’s ability to maintain its previous expansion pace.

Structural Challenges in Key Business Segment

Morgan Stanley’s analysis points to emerging headwinds in the connected television space, which has traditionally been a significant growth driver for The Trade Desk. The firm’s strategists identified structural challenges within this segment that could potentially constrain future revenue expansion. The revised price target, which now sits below current trading levels, suggests a fundamental reassessment of the company’s valuation framework and growth narrative.

Should investors sell immediately? Or is it worth buying The Trade Desk?

Contrasting Perspectives Among Analysts

Not all market experts share Morgan Stanley’s pessimistic outlook. Among 34 analysts covering the stock, the majority maintain buy recommendations. The average price target among these analysts stands at $91.62, nearly double the current trading price, indicating significant divergence in market sentiment regarding The Trade Desk’s prospects.

In a positive development, the company recently clarified uncertainty surrounding its partnership with Walmart, confirming that it retains its exclusive relationship with the retailer in the United States. Only in Mexico were adjustments made to their existing agreements.

The critical question facing investors is whether the dramatic price decline already reflects these challenges or if The Trade Desk faces deeper structural issues that could justify further downward movement. As the advertising technology landscape evolves, market participants will be watching closely to see how the company navigates these emerging headwinds in its core business segments.

Ad

The Trade Desk Stock: Buy or Sell?! New The Trade Desk Analysis from February 8 delivers the answer:

The latest The Trade Desk figures speak for themselves: Urgent action needed for The Trade Desk investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 8.

The Trade Desk: Buy or sell? Read more here...

Tags: The Trade Desk
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Puma Biotechnology Stock
Earnings

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

February 8, 2026
Quanterix Stock
Analysis

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Next Post
TAL Education Stock

TAL Education's Mixed Signals: Strong Fundamentals Meet Market Skepticism

Scientific Games Stock

Strategic Expansion and Financial Restructuring Propel Light & Wonder Forward

Nio Stock

Nio's Billion-Dollar Equity Raise Sends Stock Tumbling

Recommended

Biotechnology Stock Exchange

Analysts Bullish on Dynatrace with Price Targets on the Rise

2 years ago
The Trade Desk Stock

The Trade Desk Faces Mounting Pressure as Amazon Strikes Netflix Deal

5 months ago

Analyst Reaffirms Buy Rating on International Seaways with 66 Price Target

2 years ago
Biotechnology Stock Bull Market

KeyBanc Analyst Raises Price Target and Maintains Overweight Rating on Repligen NASDAQ RGEN

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Trending

Puma Biotechnology Stock
Earnings

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

by Jackson Burston
February 8, 2026
0

Investor attention is now firmly fixed on February 26, 2026, as Puma Biotechnology prepares to release its...

Quanterix Stock

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Puma Biotechnology Sets Date for Full-Year Financial Disclosure
  • Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test
  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com